Pro-Dex (NASDAQ:PDEX) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a research note issued on Saturday. The brokerage set a “buy” rating on the medical instruments supplier’s stock.

Pro-Dex Price Performance

Shares of NASDAQ PDEX opened at $18.97 on Friday. The firm has a market cap of $67.34 million, a P/E ratio of 14.94 and a beta of 0.99. The company has a current ratio of 3.07, a quick ratio of 1.58 and a debt-to-equity ratio of 0.36. Pro-Dex has a 1-year low of $14.47 and a 1-year high of $21.43. The business’s 50 day moving average is $17.17 and its 200-day moving average is $16.86.

Get Pro-Dex alerts:

Pro-Dex (NASDAQ:PDEX – Get Rating) last announced its earnings results on Thursday, May 4th. The medical instruments supplier reported $0.36 earnings per share for the quarter. Pro-Dex had a return on equity of 19.00% and a net margin of 9.72%. The company had revenue of $13.08 million for the quarter.

Hedge Funds Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently modified their holdings of PDEX. Renaissance Technologies LLC bought a new position in shares of Pro-Dex in the 2nd quarter valued at $168,000. JPMorgan Chase & Co. boosted its holdings in shares of Pro-Dex by 59.2% during the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock valued at $345,000 after acquiring an additional 7,762 shares in the last quarter. Punch & Associates Investment Management Inc. boosted its holdings in shares of Pro-Dex by 13.5% during the 1st quarter. Punch & Associates Investment Management Inc. now owns 63,075 shares of the medical instruments supplier’s stock valued at $1,035,000 after acquiring an additional 7,480 shares in the last quarter. UBS Group AG boosted its holdings in shares of Pro-Dex by 421.5% during the 1st quarter. UBS Group AG now owns 5,867 shares of the medical instruments supplier’s stock valued at $96,000 after acquiring an additional 4,742 shares in the last quarter. Finally, LSV Asset Management lifted its holdings in Pro-Dex by 13.9% during the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock worth $588,000 after buying an additional 4,346 shares during the period. Institutional investors own 13.49% of the company’s stock.

Pro-Dex Company Profile

(Get Rating)

Pro-Dex, Inc engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches.

Recommended Stories

• Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
• Micron Building Goodwill In Asia, Near $2 Billion Investment
• Is Twilio On The Verge Of A Comeback?
• Broadcom: All-Time Highs But Still Good Value
• Leverage AI And Build A Fortress Portfolio With Adobe
• 2 Small-Caps With Large-Cap Potential 

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.